Twist Bioscience Corp
TWST28.560USD
+2.490+9.55%
Cierre 11/21, 16:00（ET）Cotizaciones retrasadas 15 min
1.73BCap. mercado
PérdidaP/E TTM
Más Datos de Twist Bioscience Corp Compañía
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. It is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. It makes products for use across many industries, including healthcare, industrial chemicals, agriculture and academic research.
Información de Twist Bioscience Corp
Símbolo de cotizaciónTWST
Nombre de la empresaTwist Bioscience Corp
Fecha de salida a bolsaOct 31, 2018
Director ejecutivoDr. Emily M. Leproust, Ph.D.
Número de empleados923
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 31
Dirección681 Gateway Blvd.
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94080
Teléfono18007190671
Sitio Webhttps://www.twistbioscience.com/
Símbolo de cotizaciónTWST
Fecha de salida a bolsaOct 31, 2018
Director ejecutivoDr. Emily M. Leproust, Ph.D.
Ejecutivos de Twist Bioscience Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
576.72K
+32.67%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
210.55K
+45.64%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
92.71K
+5.07%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
91.58K
+36.41%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
87.86K
+40.03%
Mr. Adam Laponis
Mr. Adam Laponis
Chief Financial Officer
Chief Financial Officer
48.08K
+211.63%
Mr. Nelson C. Chan
Mr. Nelson C. Chan
Independent Director
Independent Director
22.25K
+25.16%
Dr. Melissa A. Starovasnik, Ph.D.
Dr. Melissa A. Starovasnik, Ph.D.
Independent Director
Independent Director
15.81K
+39.44%
Mr. Jan Johannessen
Mr. Jan Johannessen
Independent Director
Independent Director
5.55K
-55.92%
Mr. Robert Werner
Mr. Robert Werner
Chief Accounting Officer, Vice President
Chief Accounting Officer, Vice President
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
576.72K
+32.67%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
210.55K
+45.64%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
92.71K
+5.07%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
91.58K
+36.41%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
87.86K
+40.03%
Mr. Adam Laponis
Mr. Adam Laponis
Chief Financial Officer
Chief Financial Officer
48.08K
+211.63%
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
NGS tools
55.28M
57.55%
Synthetic genes
27.68M
28.82%
Antibody discovery
5.61M
5.84%
Oligo pools
5.42M
5.65%
DNA libraries
2.06M
2.14%
Por regiónUSD
Nombre
Ganancia
Proporción
Americas
59.39M
61.82%
EMEA
30.74M
32.00%
APAC
5.93M
6.17%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
NGS tools
55.28M
57.55%
Synthetic genes
27.68M
28.82%
Antibody discovery
5.61M
5.84%
Oligo pools
5.42M
5.65%
DNA libraries
2.06M
2.14%
Estadísticas de accionistas
Actualizado: dom., 16 de nov
Actualizado: dom., 16 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
ARK Investment Management LLC
11.00%
Artisan Partners Limited Partnership
10.48%
The Vanguard Group, Inc.
9.41%
BlackRock Institutional Trust Company, N.A.
7.87%
William Blair Investment Management, LLC
6.77%
Otro
54.46%
Accionistas
Accionistas
Proporción
ARK Investment Management LLC
11.00%
Artisan Partners Limited Partnership
10.48%
The Vanguard Group, Inc.
9.41%
BlackRock Institutional Trust Company, N.A.
7.87%
William Blair Investment Management, LLC
6.77%
Otro
54.46%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
66.15%
Investment Advisor/Hedge Fund
36.00%
Hedge Fund
9.93%
Research Firm
5.45%
Individual Investor
2.72%
Pension Fund
1.58%
Bank and Trust
0.55%
Family Office
0.17%
Insurance Company
0.07%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
566
71.88M
119.09%
+752.75K
2025Q2
575
70.44M
116.72%
-302.44K
2025Q1
585
70.23M
117.22%
-1.63M
2024Q4
578
67.47M
113.11%
-8.03M
2024Q3
588
67.80M
115.74%
-8.48M
2024Q2
579
66.59M
114.39%
-10.53M
2024Q1
565
68.18M
117.94%
-8.61M
2023Q4
559
67.81M
117.39%
-11.70M
2023Q3
560
68.09M
118.66%
-11.36M
2023Q2
577
69.42M
121.49%
-5.07M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
ARK Investment Management LLC
6.40M
10.6%
+158.85K
+2.54%
Jun 30, 2025
Artisan Partners Limited Partnership
6.41M
10.62%
+1.35M
+26.67%
Sep 30, 2025
The Vanguard Group, Inc.
5.82M
9.64%
-36.15K
-0.62%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.86M
8.05%
+226.25K
+4.89%
Jun 30, 2025
William Blair Investment Management, LLC
3.91M
6.47%
+99.74K
+2.62%
Jun 30, 2025
EdgePoint Investment Group Inc.
2.39M
3.95%
+1.27M
+114.33%
Jun 30, 2025
State Street Investment Management (US)
2.50M
4.14%
-192.68K
-7.15%
Jun 30, 2025
Amova Asset Management Co., Ltd.
2.30M
3.81%
-116.36K
-4.82%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: jue., 6 de nov
Actualizado: jue., 6 de nov
Nombre
Proporción
ARK Genomic Revolution ETF
5.08%
iShares Genomics Immunology and Healthcare ETF
3.56%
Global X Genomics & Biotechnology ETF
1.85%
ROBO Global Healthcare Technology & Innovation ETF
1.74%
ARK Innovation ETF
1.55%
WisdomTree BioRevolution Fund
1.53%
Franklin Genomic Advancements ETF
0.98%
SPDR S&P Biotech ETF
0.83%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.57%
Direxion Daily S&P Biotech Bull 3X Shares
0.43%
Ver más
ARK Genomic Revolution ETF
Proporción5.08%
iShares Genomics Immunology and Healthcare ETF
Proporción3.56%
Global X Genomics & Biotechnology ETF
Proporción1.85%
ROBO Global Healthcare Technology & Innovation ETF
Proporción1.74%
ARK Innovation ETF
Proporción1.55%
WisdomTree BioRevolution Fund
Proporción1.53%
Franklin Genomic Advancements ETF
Proporción0.98%
SPDR S&P Biotech ETF
Proporción0.83%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proporción0.57%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.43%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Twist Bioscience Corp?
Los cinco principales accionistas de Twist Bioscience Corp son:
ARK Investment Management LLC posee 6.40M acciones, lo que representa el 10.60% del total de acciones.
Artisan Partners Limited Partnership posee 6.41M acciones, lo que representa el 10.62% del total de acciones.
The Vanguard Group, Inc. posee 5.82M acciones, lo que representa el 9.64% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 4.86M acciones, lo que representa el 8.05% del total de acciones.
William Blair Investment Management, LLC posee 3.91M acciones, lo que representa el 6.47% del total de acciones.
ARK Investment Management LLC posee 6.40M acciones, lo que representa el 10.60% del total de acciones.
Artisan Partners Limited Partnership posee 6.41M acciones, lo que representa el 10.62% del total de acciones.
The Vanguard Group, Inc. posee 5.82M acciones, lo que representa el 9.64% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 4.86M acciones, lo que representa el 8.05% del total de acciones.
William Blair Investment Management, LLC posee 3.91M acciones, lo que representa el 6.47% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Twist Bioscience Corp?
Los tres principales tipos de accionista de Twist Bioscience Corp son:
ARK Investment Management LLC
Artisan Partners Limited Partnership
The Vanguard Group, Inc.
ARK Investment Management LLC
Artisan Partners Limited Partnership
The Vanguard Group, Inc.
¿Cuántas instituciones poseen acciones de Twist Bioscience Corp (TWST)?
A fecha de 2025Q3, 566 instituciones poseen acciones de Twist Bioscience Corp, con un valor de mercado combinado de aproximadamente 71.88M, lo que representa el 119.09% del total de acciones. En comparación con el 2025Q2, el accionariado institucional ha aumentado en 2.37%.
¿Cuál es la mayor fuente de ganancias de Twist Bioscience Corp?
El FY2025Q3, el segmento empresarial NGS tools generó la ganancia más alta para Twist Bioscience Corp, ascendiendo a 55.28M y representando el 57.55% de la ganancia total.
